Advertisement
Singapore markets closed

  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     

  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • Bitcoin USD

    63,824.39
    +206.88 (+0.33%)
     

  • CMC Crypto 200

    1,371.01
    +58.39 (+4.45%)
     

  • S&P 500

    4,974.26
    -36.86 (-0.74%)
     

  • Dow

    37,887.62
    +112.24 (+0.30%)
     

  • Nasdaq

    15,341.04
    -260.46 (-1.67%)
     

  • Gold

    2,409.60
    +11.60 (+0.48%)
     

  • Crude Oil

    82.96
    +0.23 (+0.28%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     

  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     

  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

New Strong Buy Stocks for July 20th

Tirthankar Chakraborty
Updated

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Agenus Inc (AGEN): This immuno-oncology (I-O) company has witnessed the Zacks Consensus Estimate for its current year earnings surging 10.2% over the last 30 days.

Agenus Inc. Price and Consensus

 

Agenus Inc. Price and Consensus | Agenus Inc. Quote

Alcobra Ltd (ADHD): This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings soaring 16.7% over the last 30 days.

Alcobra Ltd. Price and Consensus

 

Alcobra Ltd. Price and Consensus | Alcobra Ltd. Quote

BOK Financial Corporation (BOKF): This financial holding company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.5% over the last 30 days.

ADVERTISEMENT

BOK Financial Corporation Price and Consensus

 

BOK Financial Corporation Price and Consensus | BOK Financial Corporation Quote

Cellectis SA (CLLS): This company active in the field of genome engineering and genomic surgery has seen the Zacks Consensus Estimate for its current year earnings increasing 2.9% over the last 30 days.

Cellectis S.A. Price and Consensus

 

Cellectis S.A. Price and Consensus | Cellectis S.A. Quote

Chemours Co (CC): This provider of performance chemicals has witnessed the Zacks Consensus Estimate for its current year earnings improving 4.5% over the last 30 days.

Chemours Company (The) Price and Consensus

 

Chemours Company (The) Price and Consensus | Chemours Company (The) Quote

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here

Want to see all of today's Zacks Strong Buys?                                                     

You are welcome to download the full, up-to-the-minute list of 220 Zacks Rank #1 stocks free of charge. There is no better place to start your own stock search. Plus you can also access the full list of must-avoid Zacks Strong Sells and other private research. See the stocks free >>.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Cellectis S.A. (CLLS) : Free Stock Analysis Report
 
Chemours Company (The) (CC) : Free Stock Analysis Report
 
BOK Financial Corporation (BOKF) : Free Stock Analysis Report
 
Agenus Inc. (AGEN) : Free Stock Analysis Report
 
Alcobra Ltd. (ADHD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research